Thomas West - Intersect ENT President CEO, Director
| XENTDelisted Stock | USD 28.24 0.00 0.00% |
CEO
Mr. Thomas A. West is President, Chief Executive Officer of the Company., effective July 22, 2019. He has served as division president, diagnostics at Hologic Inc., a medical technology company, since October 2014, where he was responsible for managing Hologics domestic and international diagnostics solutions business and the general management of Hologics full portfolio of businesses in Latin America. From 1992 to 2014, Mr. West worked at Johnson Johnson in various roles of increasing responsibility. Most recently, he served as the Worldwide Vice President Strategy and Business Development for Johnson Johnsons Diabetes Solutions Companies, in which role he was responsible for business strategy and development initiatives across all markets. Prior to 1992, he served as President of LifeScan North America and as President of LifeScan EMEA. since 2019.
| Age | 54 |
| Tenure | 5 years |
| Phone | 650 641-2100 |
| Web | www.intersectent.com |
Thomas West Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas West against Intersect ENT stock is an integral part of due diligence when investing in Intersect ENT. Thomas West insider activity provides valuable insight into whether Intersect ENT is net buyers or sellers over its current business cycle. Note, Intersect ENT insiders must abide by specific rules, including filing SEC forms every time they buy or sell Intersect ENT'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas West over six months ago Purchase by Thomas West of 1500 shares of Noodles | ||
Thomas West over six months ago Purchase by Thomas West of 2000 shares of Noodles | ||
Thomas West over six months ago Payment of 406 shares by Thomas West of Noodles subject to Rule 16b-3 | ||
Thomas West over six months ago Payment of 757 shares by Thomas West of Noodles subject to Rule 16b-3 |
Intersect ENT Management Efficiency
The company has return on total asset (ROA) of (17.82) % which means that it has lost $17.82 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (181.73) %, meaning that it created substantial loss on money invested by shareholders. Intersect ENT's management efficiency ratios could be used to measure how well Intersect ENT manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 129.11 M in liabilities with Debt to Equity (D/E) ratio of 7.96, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Intersect ENT has a current ratio of 2.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Intersect ENT until it has trouble settling it off, either with new capital or with free cash flow. So, Intersect ENT's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intersect ENT sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intersect to invest in growth at high rates of return. When we think about Intersect ENT's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 5 records | CEO Age | ||
| Gideon BenZvi | Valens | 62 | |
| Robert Bruggeworth | Qorvo Inc | 63 | |
| Vincent Roche | Analog Devices | 64 | |
| PoWen Yen | United Microelectronics | N/A | |
| Bowen Yan | United Microelectronics | N/A | |
Management Performance
| Return On Equity | -181.73 | |||
| Return On Asset | -17.82 |
Intersect ENT Leadership Team
Elected by the shareholders, the Intersect ENT's board of directors comprises two types of representatives: Intersect ENT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intersect. The board's role is to monitor Intersect ENT's management team and ensure that shareholders' interests are well served. Intersect ENT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intersect ENT's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lisa Earnhardt, CEO and President and Director | ||
| William Vernon, Director | ||
| Christine Kowalski, COO | ||
| James Stambaugh, Vice President of Clinical and Reimbursement | ||
| Richard Kaufman, COO and Sr. VP | ||
| Casey Tansey, Independent Director | ||
| David Lehman, General Counsel | ||
| Drake Parker, Advisor – Strategic Initiatives | ||
| Amy Wolbeck, Vice President of Regulatory Affairs and Quality | ||
| Robert Binney, Chief Commercial Officer | ||
| Susan Stimson, Chief Strategy Officer | ||
| Dana Mead, Independent Director | ||
| Gwen Carscadden, Chief People Officer | ||
| Frederic Moll, Independent Director | ||
| Kieran Gallahue, Lead Director | ||
| Jeryl Hilleman, CFO | ||
| Thomas West, President CEO, Director | ||
| Cynthia Lucchese, Independent Director | ||
| Chas McKhann, Chief Commercial Officer | ||
| Teresa Kline, Director |
Intersect Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intersect ENT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -181.73 | |||
| Return On Asset | -17.82 | |||
| Profit Margin | (85.02) % | |||
| Operating Margin | (54.81) % | |||
| Current Valuation | 961.95 M | |||
| Shares Outstanding | 33.46 M | |||
| Shares Owned By Insiders | 6.80 % | |||
| Shares Owned By Institutions | 92.15 % | |||
| Number Of Shares Shorted | 1.44 M | |||
| Price To Earning | (42.68) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intersect ENT in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intersect ENT's short interest history, or implied volatility extrapolated from Intersect ENT options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Intersect Stock
If you are still planning to invest in Intersect ENT check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intersect ENT's history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |